Hao Jiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hao Jiang has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Keji Zhou
State Key Laboratory of Integrated Chips and Systems, Frontier Institute of Chip and System, Fudan University, Shanghai, China
2 shared publications - Qi Liu
Fudan University
2 shared publications - Xumeng Zhang
Frontier Institute of Chip and System Fudan University Shanghai China
2 shared publications - Chenggao Zhang
Zhejiang Laboratory, Hangzhou, China
1 shared publication Chenyang Li
State Key Laboratory of Integrated Chips and Systems, Frontier Institute of Chip and System, Fudan University, Shanghai, China
1 shared publicationFangduo Zhu
State Key Laboratory of Integrated Chips and Systems, Frontier Institute of Chip and System, Fudan University, Shanghai, China
1 shared publication
Latest Publications
- 9 January 2024
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Circuits and Systems II: Express Briefs
- Vol. 71 (5) , 2804-2808
A Scalable Area-Efficient Low-Delay Asynchronous AER Circuits Design for Neuromorphic Chips
In multi-core neuromorphic chips, asynchronous Address-Event-Representation (AER) circuit is commonly used to encode and transmit spikes between neurons in different cores. Existing asynchronous AER circuits using bundled data protocol are mainly constructed in pipelined tree structure. The delay and area of these circuits increase significantly as the input channel number increases. This brief proposes a new AER unit using mask-based arbitration scheme, which is able to significantly reduce the area and delay for sparse event at the cost of high power consumption and low throughput. A dual-level mask AER structure is proposed to mitigate the drawbacks. According to the simulation result, the dual-level mask AER has a reduction of 48% in area and 17%-39% in delay with respect to pipelined tree AER, while the power consumption increasement is no more than 19% of pipelined tree. What’s more, the dual-level scheme exhibits competitive performance in delay when compared to the delay-insensitive AER schemes.
- 9 January 2024
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Circuits and Systems II: Express Briefs
- Vol. 71 (5) , 2804-2808
A Scalable Area-Efficient Low-Delay Asynchronous AER Circuits Design for Neuromorphic Chips
In multi-core neuromorphic chips, asynchronous Address-Event-Representation (AER) circuit is commonly used to encode and transmit spikes between neurons in different cores. Existing asynchronous AER circuits using bundled data protocol are mainly constructed in pipelined tree structure. The delay and area of these circuits increase significantly as the input channel number increases. This brief proposes a new AER unit using mask-based arbitration scheme, which is able to significantly reduce the area and delay for sparse event at the cost of high power consumption and low throughput. A dual-level mask AER structure is proposed to mitigate the drawbacks. According to the simulation result, the dual-level mask AER has a reduction of 48% in area and 17%-39% in delay with respect to pipelined tree AER, while the power consumption increasement is no more than 19% of pipelined tree. What’s more, the dual-level scheme exhibits competitive performance in delay when compared to the delay-insensitive AER schemes.
- 16 October 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Journal on Emerging and Selected Topics in Circuits and Systems
- Vol. 13 (4) , 975-985
Multicore Spiking Neuromorphic Chip in 180-nm With ReRAM Synapses and Digital Neurons
Neuromorphic computing based on spike neural networks (SNNs) exhibits great potential in reducing energy consumption in hardware systems. Resistive random-access memory (ReRAM) is regarded as a promising candidate to construct neuromorphic hardware, attributing to their high-density, nonvolatile, and compute-in-memory capability. However, the ReRAM-based neuromorphic chips are still in their infancy, cannot support multicore or with limited neuron configurability. To alleviate these problems, we propose a hybrid multicore SNN chip based on 60 K-ReRAM synapses and 480-digital neurons in the 180 nm node, achieving a synaptic density of 20K bit/mm 2 per core. To improve the efficiency of inter-core communication, we adopt a network-on-chip architecture with a bit character encoding strategy. In addition, an adaptive multiplier-less digital neuron is designed to support both Izhikevich and leaky integrate-and-fire models through register bit control, meeting different application scenarios. Finally, we evaluate the performance of our chip on the MNIST dataset recognition tasks, achieving 97.65% accuracy. Also, a minimum energy per synaptic operation (SOP) of 6.6 pJ in the 180 nm node is obtained, outperforming the TrueNorth’s 26 pJ in 28 nm. These results show that our design has a great potential for large-scale SNN implementations and may pave the way for designing high-efficient neuromorphic hardware with ReRAM technology.
- 16 October 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Journal on Emerging and Selected Topics in Circuits and Systems
- Vol. 13 (4) , 975-985
Multicore Spiking Neuromorphic Chip in 180-nm With ReRAM Synapses and Digital Neurons
Neuromorphic computing based on spike neural networks (SNNs) exhibits great potential in reducing energy consumption in hardware systems. Resistive random-access memory (ReRAM) is regarded as a promising candidate to construct neuromorphic hardware, attributing to their high-density, nonvolatile, and compute-in-memory capability. However, the ReRAM-based neuromorphic chips are still in their infancy, cannot support multicore or with limited neuron configurability. To alleviate these problems, we propose a hybrid multicore SNN chip based on 60 K-ReRAM synapses and 480-digital neurons in the 180 nm node, achieving a synaptic density of 20K bit/mm 2 per core. To improve the efficiency of inter-core communication, we adopt a network-on-chip architecture with a bit character encoding strategy. In addition, an adaptive multiplier-less digital neuron is designed to support both Izhikevich and leaky integrate-and-fire models through register bit control, meeting different application scenarios. Finally, we evaluate the performance of our chip on the MNIST dataset recognition tasks, achieving 97.65% accuracy. Also, a minimum energy per synaptic operation (SOP) of 6.6 pJ in the 180 nm node is obtained, outperforming the TrueNorth’s 26 pJ in 28 nm. These results show that our design has a great potential for large-scale SNN implementations and may pave the way for designing high-efficient neuromorphic hardware with ReRAM technology.
- 1 June 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (16_suppl) , 7052
Anti–PD-1 antibody (sintilimab) plus decitabine as first-line treatment for patients with higher-risk myelodysplastic syndrome (MDS): Preliminary results from a single-arm, open-label, phase II study.
7052 Background: Hypomethylating agents (HMAs) are the preferred treatment for untreated patients (pts) with higher-risk MDS, but the survival of pts after HMAs treatment is poor. It has been demonstrated that the PD-1/PD-L1 expression was upregulated by HMAs in MDS pts, providing a strong rationale for combining HMAs with PD-1 antibody for MDS treatment. Therefore, this single-arm, open-label, clinical trial was performed to evaluate safety and efficacy of Sintilimab plus decitabine for pts with higher-risk MDS (ChiCTR2100044393). Methods: Adult pts with higher-risk MDS by the IPSS-R were enrolled. Patients received decitabine 20mg/m2 intravenously daily for 5 days and sintilimab 200mg IV starting on the first and 22nd day of a cycle every 42 days until unacceptable toxicity, relapse, or progression, for a maximum of 8 cycles. The primary endpoint was overall response rate (CR+PR+mCR). Simon’s optimal two-stage design was employed.If five or more pts in stage I (13 pts) achieved ORR, the study would enroll 34 additional pts in stage II (47 pts). Secondary endpoints included safety, and survival outcomes. The relationship between expression levels of immune-checkpoint and efficacy of the combination therapy, as well as other potential biomarkers were also explored via genomic profiling. Results: At data cut-off (January 31, 2022), 21 pts were enrolled with a median follow-up time of 5.8 months. The median age of pts was 64 years (range 30-83), and the other characteristics are summarised in Table.The ORR was 62%,with six pts reaching complete response (CR),four pts reaching marrow CR and three pts achieved marrow CR+ hematologic improvement (HI). In addition,four pts reaching HI. The most common grade 3 TEAEs( > 10%) were febrile neutropenia (76.2%) and pulmonary infection (38.1%). No grade 4 TEAEs and treatment-related deaths occurred. A total of 12 pts (57.1%)experienced immune-related adverse event, including rash (28.6%), pneumonia (9.5%), hypothyroidism (9.5%), elevated serum bilirubin (4.8%) and transpeptidase (4.8%), which were all resolved by glucocorticoid. In these 21 pts, the most frequently mutated genes are ASXL1(28.6%), RUNX1 (14.3%) and TET2(14.3%). Updated biomarker data will be presented during the ASCO meeting. Conclusions: To the best of our knowledge, this is the first study to evaluate the efficacy and safety of sintilimab plus decitabine in pts with untreated higher-risk MDS. The preliminary results demonstrate that the combination therapy is relatively safe with anti-tumor activity. Clinical trial information: ChiCTR2100044393. [Table: see text]
- 1 June 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (16_suppl) , 7052
Anti–PD-1 antibody (sintilimab) plus decitabine as first-line treatment for patients with higher-risk myelodysplastic syndrome (MDS): Preliminary results from a single-arm, open-label, phase II study.
7052 Background: Hypomethylating agents (HMAs) are the preferred treatment for untreated patients (pts) with higher-risk MDS, but the survival of pts after HMAs treatment is poor. It has been demonstrated that the PD-1/PD-L1 expression was upregulated by HMAs in MDS pts, providing a strong rationale for combining HMAs with PD-1 antibody for MDS treatment. Therefore, this single-arm, open-label, clinical trial was performed to evaluate safety and efficacy of Sintilimab plus decitabine for pts with higher-risk MDS (ChiCTR2100044393). Methods: Adult pts with higher-risk MDS by the IPSS-R were enrolled. Patients received decitabine 20mg/m2 intravenously daily for 5 days and sintilimab 200mg IV starting on the first and 22nd day of a cycle every 42 days until unacceptable toxicity, relapse, or progression, for a maximum of 8 cycles. The primary endpoint was overall response rate (CR+PR+mCR). Simon’s optimal two-stage design was employed.If five or more pts in stage I (13 pts) achieved ORR, the study would enroll 34 additional pts in stage II (47 pts). Secondary endpoints included safety, and survival outcomes. The relationship between expression levels of immune-checkpoint and efficacy of the combination therapy, as well as other potential biomarkers were also explored via genomic profiling. Results: At data cut-off (January 31, 2022), 21 pts were enrolled with a median follow-up time of 5.8 months. The median age of pts was 64 years (range 30-83), and the other characteristics are summarised in Table.The ORR was 62%,with six pts reaching complete response (CR),four pts reaching marrow CR and three pts achieved marrow CR+ hematologic improvement (HI). In addition,four pts reaching HI. The most common grade 3 TEAEs( > 10%) were febrile neutropenia (76.2%) and pulmonary infection (38.1%). No grade 4 TEAEs and treatment-related deaths occurred. A total of 12 pts (57.1%)experienced immune-related adverse event, including rash (28.6%), pneumonia (9.5%), hypothyroidism (9.5%), elevated serum bilirubin (4.8%) and transpeptidase (4.8%), which were all resolved by glucocorticoid. In these 21 pts, the most frequently mutated genes are ASXL1(28.6%), RUNX1 (14.3%) and TET2(14.3%). Updated biomarker data will be presented during the ASCO meeting. Conclusions: To the best of our knowledge, this is the first study to evaluate the efficacy and safety of sintilimab plus decitabine in pts with untreated higher-risk MDS. The preliminary results demonstrate that the combination therapy is relatively safe with anti-tumor activity. Clinical trial information: ChiCTR2100044393. [Table: see text]